

Abbott India Limited
Godrej BKC, Plot C-68,"G"Block,
15-16th Floor, Bandra-Kurla Complex,
Near MCA Club, Bandra (E),
Mumbai - 400 051. India

Registered Office:
3, Corporate Park,
Sion Trombay Road,
Mumbai - 400 071.India

Tel: (91-22) 5046 1000/2000
Fax : (91-22) 5016 9400
E-mail : webmasterindia@abbott.com
Website : www.abbott.co.in
CIN: L24239MH1944PLC007330



March 31, 2020

Corporate Relations Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai- 400 001

Kind attention: Ms Kruti Shah

Dear Madam,

Subject: Clarification on news item appearing in "www.moneycontrol.com"

This is with reference to your letter L/SURV/ONL/RV/NK/ (2019-2020)/ 162 dated March 30, 2020 which we received via email at 1.26 p.m.

In this connection, we would like to inform you that the Company has been adhering to all the disclosure requirements under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Further, Abbott Laboratories, through a press release issued on March 27, 2020, announced that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for the molecular point-of-care test for the detection of novel coronavirus (COVID-19). The said press release is attached for your kind reference. It did not mention Abbott India Limited or the tests being made available in India.

With regards to the specific news article that appeared on 'Money Control,' we hereby state that the paragraph: "**At the moment Abbott's testing will be confined to the US, but given the urgency of the situation, it could be a matter of weeks before it is available in other countries including India**" is factually incorrect as it relates to India and is inconsistent with public communications issued by Abbott.

We trust the above clarifies the matter.

Thank you.

Abbott India Limited

A handwritten signature in black ink, appearing to read 'Krupa', with a horizontal line drawn through it.

**Krupa Anandpara
Company Secretary
Membership No.: ACS 16536**

Encl: a/a

ABBOTT LAUNCHES MOLECULAR POINT-OF-CARE TEST TO DETECT NOVEL CORONAVIRUS IN AS LITTLE AS FIVE MINUTES

- The Abbott ID NOW™ COVID-19 test brings rapid testing to the front lines
- Test to run on Abbott's point-of-care ID NOW platform - a portable instrument that can be deployed where testing is needed most
- ID NOW has the largest molecular point-of-care installed base in the U.S. and is available in a wide range of healthcare settings
- Abbott will be making ID NOW COVID-19 tests available next week and expects to ramp up manufacturing to deliver 50,000 tests per day
- This is the company's second test to receive Emergency Use Authorization by the FDA for COVID-19 detection; combined, Abbott expects to produce about 5 million tests per month

ABBOTT PARK, Ill., March 27, 2020 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for the [fastest available molecular point-of-care test](#) for the detection of novel coronavirus (COVID-19), delivering positive results in as little as five minutes and negative results in 13 minutes. The test will run on the company's ID NOW™ platform, providing rapid results in a wide range of healthcare settings such as physicians' offices, urgent care clinics and hospital emergency departments.

The ID NOW platform is small, lightweight (6.6 pounds) and portable (the size of a small toaster), and uses molecular technology, which is valued by clinicians and the scientific community for its high degree of accuracy. ID NOW is already the most widely available molecular point-of-care testing platform in the U.S. today.

"The COVID-19 pandemic will be fought on multiple fronts, and a portable molecular test that offers results in minutes adds to the broad range of diagnostic solutions needed to combat this virus," said Robert B. Ford, president and chief operating officer, Abbott. "With rapid testing on ID NOW, healthcare providers can perform molecular point-of-care testing outside the traditional four walls of a hospital in outbreak hotspots."

Abbott will be making ID NOW COVID-19 tests available next week to healthcare providers in urgent care settings in the U.S., where the majority of ID NOW instruments are in use today. The company is working with the Administration to deploy tests to areas where they can have the greatest impact.

The arrival of the Abbott ID NOW COVID-19 test comes a week after the company [launched](#) its Abbott *m2000*™ RealTime SARS-CoV-2 EUA test, which runs on the *m2000*™ RealTime System located in hospital and reference labs around the world. Between the two platforms, Abbott expects to produce about 5 million tests per month.

About the ID NOW™ Molecular Platform

As the world leader in point-of-care diagnostics, Abbott is adding its expertise and scale to help fight the COVID-19 global pandemic. First introduced in 2014, [ID NOW](#) is the leading molecular point-of-care platform for Influenza A & B, Strep A and RSV testing in the U.S.

ID NOW is a rapid, instrument-based, isothermal system for the qualitative detection of infectious diseases. Its unique isothermal nucleic acid amplification technology provides molecular results in just minutes, allowing clinicians to make evidence-based clinical decisions during a patient visit.

About Abbott

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 107,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com, on LinkedIn at www.linkedin.com/company/abbott-/, on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews and @AbbottGlobal.

The ID NOW COVID-19 EUA has not been FDA cleared or approved. It has been authorized by the FDA under an emergency use authorization for use by authorized laboratories and patient care settings. The test has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens, and is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

SOURCE Abbott

For further information: Abbott Media: John Koval, (224) 668-5355; Darcy Ross, (224) 667-3655; Abbott Investor Relations: Laura Dauer, (224) 667-2299